Omacetaxine mepesuccinate - Teva Pharmaceutical Industries
Alternative Names: C41443; Ceflatonin®; CGX-635; CXS-635; HHT; Homoharringtonine; Homoharringtonine-ChemGenex; NCI 141633; Omapro™; SynriboLatest Information Update: 02 Oct 2021
At a glance
- Originator ChemGenex Pharmaceuticals; Stragen Pharma SA
- Developer ChemGenex Pharmaceuticals; Roswell Park Cancer Institute; Teva Pharmaceutical Industries; University of Hong Kong; University of Texas M. D. Anderson Cancer Center
- Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
- Mechanism of Action Apoptosis stimulants; Cyclin D1 inhibitors; MCL1 protein inhibitors; Protein synthesis inhibitors; Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
- No development reported Haematological malignancies
- Discontinued Acute promyelocytic leukaemia; Solid tumours
Most Recent Events
- 21 Feb 2021 Omacetaxine mepesuccinate is still in phase II trials for Acute myeloid leukaemia in Hong Kong (NCT03135054) (NDR batch 18)
- 10 Dec 2020 University of Hong Kong completes enrolment in a phase II trial in Acute myeloid leukaemia (Newly diagnosed, Second-line therapy or greater, Combination therapy) in HongKong (NCT03135054)
- 14 Apr 2020 M.D. Anderson Cancer Center and Teva Pharmaceuticals completes the phase II trial in myelodysplastic syndrome in USA (SC) (NCT02159872)